

13th November, 2019

To,
The Manager,
Dept. of Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001

Dear Sir/Madam,

Sub: Submission of Un-Audited Financial Results along with Limited Review Report as per Regulation 33 of SEBI (LODR) Regulations, 2015 -Reg

Ref: BSE Scrip Code: 511509

Please find enclosed herewith the following documents in terms of Regulation 33 of SEBI (LODR) Regulations, 2015:

1. Un-audited Consolidated and Standalone financial results for the Second quarter and Half year ended 30th September, 2019.
2. Consolidated and Standalone Cash flow statement as on 30th September, 2019.
3. Standalone and consolidated Statement of Assets and Liabilities as on 30th September, 2019.
4. Limited Review Report on Consolidated financial results for the Second quarter and Half year ended 30th September, 2019 issued by the Statutory Auditors.
5. Limited Review Report on Standalone financial results for the Second quarter and Half year ended 30th September, 2019 issued by the Statutory Auditors.

This is for your information on record.

Thanking You
Yours Truly

For Vivo Bio Tech Ltd



K.T.V. Kaladhar
Whole Time Director & CFO
DIN: 08450361



Vivo Bio Tech Ltd.
Your Drug Discovery Partner

Vivo Bio Tech Ltd
8-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate
Road No.1, Banjara Hills, Hyderabad-500034
E-mail:investors@vivo.bio.com CIN: L65993TG1987PLC007163



| S.No. | PARTICULARS | UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QTR AND HALF YEAR ENDED 30TH SEPTEMBER, 2019 | | | | | | Rs. in Lacs | |
|-------|--|---|----------------|----------------|-----------------|----------------|----------------|-------------|--|
| | | QUARTER ENDED | | | HALF YEAR ENDED | | | Year Ended | |
| | | 30.09.2019 | 30.06.2019 | 30.09.2018 | 30.09.2019 | 30.09.2018 | 31.03.2019 | Audited | |
| | | Un-Audited | Un-Audited | Un - Audited | Un-Audited | Un - Audited | Un - Audited | | |
| I | Revenue from operations | 1,354.44 | 1334.55 | 1406.45 | 2688.99 | 2764.74 | 5583.35 | | |
| II | Other Income | 2.93 | 0.00 | 0.00 | 2.93 | 0.46 | 1.21 | | |
| III | Total Income | 1,357.37 | 1334.55 | 1406.45 | 2691.92 | 2765.20 | 5584.56 | | |
| IV | Expenses | (33.56) | -96.04 | (172.32) | (129.60) | (232.73) | -65.01 | | |
| | a) Increase/(decrease) in stock in trade and WIP | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | | |
| | b) Consumption of Raw materials | 319.36 | 204.4 | 478.25 | 523.76 | 834.85 | 1240.92 | | |
| | c) Purchase of traded goods | 255.60 | 221.93 | 219.27 | 477.53 | 426.04 | 957.8 | | |
| | d) Employees Cost | 126.45 | 126.44 | 128.79 | 252.89 | 244.77 | 505.77 | | |
| | e) Depreciation and amortisation | 75.15 | 87.48 | 68.84 | 162.63 | 135.25 | 264.09 | | |
| | f) Finance Cost | 446.13 | 626.52 | 490.48 | 1072.65 | 984.34 | 2119.96 | | |
| | g)Administrative Expenditure | 1,189.13 | 1170.73 | 1213.31 | 2359.86 | 2392.52 | 5023.53 | | |
| V | Total | 168.25 | 163.82 | 193.14 | 332.07 | 372.68 | 561.03 | | |
| VI | Profit Before Tax & Exceptional Item (III-IV) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 378.36 | | |
| VII | Exceptional Item | 19.16 | 63.65 | 42.18 | 82.81 | 76.72 | 37.6 | | |
| | Profit Before Tax | (84.32) | -19.98 | (95.60) | (104.30) | (99.73) | -79.93 | | |
| | Tax Expense | (65.17) | 43.67 | (53.42) | (21.50) | (23.01) | -42.33 | | |
| | Total Tax Expense | 233.41 | 120.15 | 246.56 | 353.56 | 395.69 | 225 | | |
| VIII | Net Profit After Tax (V-VI) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | | |
| IX | Minority Interest | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | | |
| X | Other Comprehensive Income | 233.41 | 120.15 | 246.56 | 353.56 | 395.69 | 225 | | |
| XI | a-Items that will be reclassified to profit or loss (Net of Tax) | 1,275.05 | 1275.05 | 995.05 | 1275.05 | 995.05 | 1235.05 | | |
| XII | Total other Comprehensive Income(VII+VIII+IX) | 1,83 | 0.94 | 2.48 | 2.77 | 3.98 | 1.82 | | |
| | Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units) | 1,83 | 0.94 | 2.48 | 2.77 | 3.98 | 1.76 | | |
| | Earnings per equity share: | | | | | | | | |
| | 1)Basic | 1.83 | 0.94 | 2.48 | 2.77 | 3.98 | 1.76 | | |
| | 2)Diluted | 1.83 | 0.94 | 2.48 | 2.77 | 3.98 | 1.76 | | |

| UNAUDITED STAND ALONE FINANCIAL RESULTS FOR THE QTR AND HALF YEAR ENDED 30TH SEPTEMBER, 2019 | | | | | | | | | |
|--|---|----------------|----------------|----------------|-----------------|----------------|----------------|------------|---------|
| S.No. | PARTICULARS | QUARTER ENDED | | | HALF YEAR ENDED | | | Year Ended | |
| | | 30.09.2019 | 30.06.2019 | 30.09.2018 | 30.09.2019 | 30.09.2018 | 31.03.2019 | Year Ended | |
| | | Un-Audited | Un-Audited | Un - Audited | Un-Audited | Un - Audited | Audited | Un-Audited | Audited |
| I | Revenue from operations | 1354.44 | 1334.55 | 1,406.45 | 2688.99 | 2,764.74 | 5583.34 | | |
| II | Other Income | 2.93 | 0 | 0.00 | 2.93 | 0.46 | 1.21 | | |
| III | Total Income | 1357.37 | 1334.55 | 1406.45 | 2691.92 | 2765.20 | 5584.55 | | |
| IV | Expenses | | | | | | | | |
| | a) Increase/(decrease) in stock in trade and WIP | (33.56) | -96.04 | -172.32 | (129.60) | (232.73) | -65.01 | | |
| | b) Consumption of Raw materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | | |
| | c) Purchase of traded goods | 319.36 | 204.4 | 478.25 | 523.76 | 834.85 | 1240.92 | | |
| | d) Employees Cost | 255.60 | 221.93 | 219.27 | 477.53 | 426.04 | 957.80 | | |
| | e) Depreciation and amortisation | 126.45 | 126.44 | 128.79 | 252.89 | 244.77 | 505.77 | | |
| | f) Finance Cost | 75.15 | 87.48 | 68.84 | 162.63 | 135.25 | 264.09 | | |
| | g)Administrative Expenditure | 446.13 | 626.52 | 490.48 | 1072.65 | 984.34 | 2119.96 | | |
| | Total | 1189.13 | 1170.73 | 1213.31 | 2359.86 | 2392.52 | 5023.53 | | |
| V | Profit Before Tax (III-IV) | 168.25 | 163.82 | 193.14 | 332.07 | 372.68 | 561.02 | | |
| | Exceptional Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 378.36 | | |
| VI | Profit Before Tax | 168.25 | 163.82 | 193.14 | 332.07 | 372.68 | 182.66 | | |
| VII | Tax Expense | 19.16 | 63.65 | 42.18 | 82.81 | 76.72 | 37.60 | | |
| | a. Current Tax | (84.32) | -19.98 | -95.6 | (104.30) | (99.73) | -79.93 | | |
| | b. Deferred tax | (65.17) | 43.67 | (53.42) | (21.50) | (23.01) | (42.33) | | |
| | Total Tax Expense | 233.41 | 120.15 | 246.56 | 353.56 | 395.69 | 224.99 | | |
| | Net Profit After Tax (V-VI) | | | | | | | | |
| VIII | Other Comprehensive Income | | | | | | | | |
| | a. Items that will be reclassified to profit or loss (Net of Tax) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | | |
| IX | Total other Comprehensive Income(VII+VIII+IX) | 233.41 | 120.14 | 246.55 | 353.56 | 395.68 | 225 | | |
| X | Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units) | 1275.05 | 1275.05 | 995.05 | 1275.05 | 995.05 | 1235.05 | | |
| XI | Earnings per equity share: | | | | | | | | |
| | 1)Basic | 1.83 | 0.94 | 2.48 | 2.77 | 3.98 | 1.82 | | |
| | 2)Diluted | 1.83 | 0.94 | 1.93 | 2.77 | 3.10 | 1.76 | | |



Vivo Bio Tech Ltd
 8-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate
 Road No.1, Banjara Hills, Hyderabad-500034
 E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

Vivo Bio Tech Ltd.
 Your Drug Discovery Partner

| Particulars | | Rs. In Lacs | | |
|-------------|--|---|---|--------------------------------------|
| | | As at 30th September, 2019 Un-Audited | As at 30th September, 2018 Un-Audited | As at 31st March, 2019 Audited |
| A. | Cash Flow from Operating Activities: | | | |
| | Net Profit/ (Loss) before taxation and extraordinary items | 332 | 373 | 182 |
| | Adjustments for: | | | |
| | Depreciation | 253 | 245 | 506 |
| | Amortised Expenses | - | - | 0 |
| | Interest expenses | 163 | 135 | 264 |
| | Operating Profit before Working Capital Changes | 748 | 753 | 952 |
| | Working Capital Changes | | | |
| | Trade and other receivables including Inventory | 102 | (190) | (68) |
| | Trade and Other payables | 357 | (69) | (740) |
| | Cash Generated from Operations | 1,206 | 494 | 144 |
| | Interest paid | 163 | 134 | 264 |
| | Taxation for the year | (21) | (23) | (42) |
| | Net Cash from Operating Activities | 1,065 | 383 | (77) |
| B. | Cash Flow from Investing Activities: | | | |
| | Purchase of Fixed Assets | (947) | (230) | (353) |
| | Investment | - | - | - |
| | Net Cash used in Investing Activities | (947) | (230) | (353) |
| C. | Cash Flow From Financial Activities: | | | |
| | Proceeds from Equity Shares | 90 | 30 | 572 |
| | Net Proceeds from Long Term Borrowings | (206) | (574) | (500) |
| | Net Cash used in Financing Activities | (116) | (544) | 72 |
| | Net Increase in cash and cash equivalents | 2 | (391) | (358) |
| | Cash and Cash equivalents as at Beginning of the Year | 56 | 415 | 415 |
| | Cash and Cash equivalents as at 30.09.2019 | 58 | 24 | 57 |



Vivo Bio Tech Ltd
 8-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate
 Road No.1, Banjara Hills, Hyderabad-500034
 E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

Vivo Bio Tech Ltd.
 Your Drug Discovery Partner

| Particulars | | Standalone Cash Flow Statement for the Half Year Ended 30th September, 2019 | | |
|-------------|--|---|----------------------|------------------|
| | | Rs. In Lacs | | |
| | | As at | As at | As at |
| | | 30th September, 2019 | 30th September, 2018 | 31st March, 2019 |
| | | Un-Audited | Un-Audited | Audited |
| A. | Cash Flow from Operating Activities: | | | |
| | Net Profit/ (Loss) before taxation and extraordinary items | 332 | 373 | 183 |
| | Adjustments for: | | | |
| | Depreciation | 253 | 245 | 506 |
| | Amortised Expenses | - | - | - |
| | Interest expenses | 163 | 135 | 264 |
| | Operating Profit before Working Capital Changes | 748 | 753 | 953 |
| | Working Capital Changes | | | |
| | Trade and other receivables Including Inventory | 5.65 | (188) | (69) |
| | Trade and Other payables | 137 | (68) | (740) |
| | Cash Generated from Operations | 890 | 496 | 143 |
| | Interest paid | 163 | 135 | 264 |
| | Taxation for the year | (21) | (23) | (42) |
| | Net Cash from Operating Activities | 749 | 384 | (78) |
| B. | Cash Flow from Investing Activities: | | | |
| | Purchase of Fixed Assets | (630) | -230 | (353) |
| | Investment | (1) | - | - |
| | Net Cash used in Investing Activities | (631) | (230) | (353) |
| C. | Cash Flow From Financial Activities: | | | |
| | Proceeds from Equity Shares | 90 | 30 | 570 |
| | Net Proceeds from Long Term Borrowings | (206) | (574) | (500) |
| | Net Cash used in Financing Activities | (116) | (544) | 70 |
| | Net increase in cash and cash equivalents | 1 | (390) | (361) |
| | Cash and Cash equivalents as at Beginning of the Year | 53 | 415 | 415 |
| | Cash and Cash equivalents as at 30.09.2019 | 54 | 24 | 54 |



Vivo Bio Tech Ltd
 8-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate
 Road No.1, Banjara Hills, Hyderabad-500034
 E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

Vivo Bio Tech Ltd.
 Your Drug Discovery Partner

| Statement of Assets and Liabilities at at 30th September, 2019 | | Rs. In Lacs | | | |
|--|---|--------------------------|----------------------|--------------------------|----------------------|
| Sl.No | Particulars | Standalone | | Consolidated | |
| | | As At September 30, 2019 | As At March 31, 2019 | As At September 30, 2019 | As At March 31, 2019 |
| | | Un-Audited | Audited | Un-Audited | Audited |
| I | ASSETS | | | | |
| | Non-Current Assets | | | | |
| | Fixed Assets | | | | |
| | Property, Plant and Equipment | 2,622.24 | 2,461.01 | 2,958.26 | 2,480.42 |
| | Capital Work-In-Progress | - | 6.60 | - | 6.60 |
| | Intangible Assets | 743.55 | 520.81 | 743.55 | 520.81 |
| | Financial Assets | | | | |
| | Non-Current Investments | 4.00 | 3.00 | - | - |
| | Long Term Loans and Advances | 7.55 | 9.74 | 9.49 | 11.38 |
| | Other Non Current Assets | - | - | - | - |
| | Total Non-Current Assets | 3,377.34 | 3,001.17 | 3,711.30 | 3,019.21 |
| | Current Assets | | | | |
| | Inventories | 953.23 | 823.63 | 953.23 | 823.63 |
| | Financial Assets | - | - | - | - |
| | Trade Receivables | 827.29 | 841.00 | 827.29 | 841.00 |
| | Cash and cash equivalents | 54.17 | 52.76 | 58.09 | 56.27 |
| | Short term loans and advances | 634.58 | 734.25 | 516.57 | 712.47 |
| | Other current assets | 35.25 | 54.93 | 35.25 | 54.93 |
| | Total Current Assets | 2,504.52 | 2,506.57 | 2,390.44 | 2,488.29 |
| | TOTAL ASSETS | 5,881.86 | 5,507.74 | 6,101.75 | 5,507.51 |
| II | EQUITY AND LIABILITIES | | | | |
| | Equity | | | | |
| | Equity Share Capital | 1,275.05 | 1,235.05 | 1,275.05 | 1,235.05 |
| | Other Equity | 1,896.75 | 1,463.19 | 1,895.73 | 1,462.20 |
| | Money Received Against Share Warrants | - | 30.00 | - | 30.00 |
| | Total Equity | 3,171.80 | 2,728.24 | 3,170.78 | 2,727.25 |
| | Liabilities | | | | |
| | Non Current liabilities | | | | |
| | Financial Liabilities | | | | |
| | Borrowings | 683.74 | 889.94 | 684.38 | 890.46 |
| | Defered Tax Liabilities(Net) | 39.33 | (23.69) | 39.33 | (23.69) |
| | Long term provisions | (127.99) | 35.86 | (127.99) | 35.86 |
| | Total Non Current Liabilities | 595.08 | 902.11 | 595.72 | 902.63 |
| | Current Liabilities | | | | |
| | Financial Liabilities | | | | |
| | Borrowings | 1,393.64 | 1,277.23 | 1,613.64 | 1,277.23 |
| | Trade Payable & Other Current Liabilities | 491.52 | 490.02 | 491.52 | 490.02 |
| | Provisions | 229.82 | 110.15 | 230.09 | 110.38 |
| | Total Current Liabilities | 2,114.98 | 1,877.40 | 2,335.25 | 1,877.63 |
| | Total Equity & Liabilities | 5,881.86 | 5,507.74 | 6,101.75 | 5,507.51 |

Place: Hyderabad
 Date: 13th November, 2019

For Vivo Bio Tech Ltd



K.T.V. Kaladhar

K.T.V. KALADHAR
 Whole Time Director & CFO
 DIN:08450361

Notes

1. The above un-audited financial results for the quarter and Half Year ended September 30, 2019 have been subject to a limited review by the statutory Auditors, are recommended by the Audit Committee were considered and approved by the board of directors at their meeting held on 13th November, 2019
2. The above un-audited financial results have been prepared in accordance with the IND AS notified under the Companies (Indian Accounting Standards) Rules, 2015.
3. The Company operates in single Segments Viz., Bio Technology. Hence segmental reporting is not required.
4. An Extract of the detailed format of unaudited financial results filed with stock exchange under Regulation 33 of SEBI(Listing obligations and Disclosure Requirements) Regulations,2015 will be published in Newspaper.
5. Previous year's/period's figures are rearranged/ regrouped wherever necessary

Place: Hyderabad

Date: 13th November, 2019



For Vivo Bio Tech Limited



K.T.V. Kaladhar
Whole Time Director & CFO
DIN: 08450361



P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com


Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended.

Review Report to
The Board of Directors
Vivo Bio Tech Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Finance Results of Vivo Bio Tech Limited which includes its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended September 30, 2019 and year to date from April 01, 2019 to September 30, 2019 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). Attention is drawn to the fact that the consolidated figures for the net cash inflows for the corresponding period from April 01, 2018 to September 30, 2018, as reported in these unaudited consolidated financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.

2. The Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in India Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SBE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Regulations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable..

4. The Statement includes the results of the following entities:

- a) VIVO BIO DISCOVERY SERVICES PRIVATE LIMITED
- b) SURLOGIC LIFE CONSULTANCY PRIVATE LIMITED
- c) VIOBIO LABS PRIVATE LIMITED
- d) DONAKANTI CONSULTANCY SERVICES PRIVATE LIMITED

5. The accompanying Statement includes interim financial results and other financial information of 4 Subsidiaries which reflects total assets of Rs. 3,41,88,716 as at September 30,2019, total revenues of Rs. Nil/- total Profit after tax of Rs .Nil/-total comprehensive income of Rs. Nil for the quarter ended September 30, 2019 and for the period from April 01, 2019 to September 30, 2019, respectively and net cash inflow of Rs.26,500/- for the period from April 01, 2019 to September 30, 2019, and these interim financial results and other financial information has been reviewed by parent company Management and submitted to us. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.


For P C N & Associates
Chartered Accountants
FRN:016016S


Chandra Babu M
Partner

M.No. 227849

Date: 13-11-2019

Place: Hyderabad



UDIN: 19227849AAAALL9128



P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com


Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended.

Review Report to
The Board of Directors
Vivo Bio Tech Limited

1. We have reviewed the accompanying Statement of Unaudited standalone Finance Results of Vivo Bio Tech Limited for the quarter ended September 30, 2019 and year to date from April 01, 2019 to September 30, 2019 (the "Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). Attention is drawn to the fact that the figures for the net cash inflows for the corresponding period from April 01, 2018 to September 30, 2018, as reported in these unaudited standalone financial results have been approved by the Board of Directors, but have not been subjected to review.

2. The Statement, which is the responsibility of the company Management and approved by the company Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in India Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SBE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.







P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P C N & Associates
Chartered Accountants
FRN: 016016S


Chandra babu M
Partner
M.No. 227849



Date: 13-11-2019
Place: Hyderabad

UDIN: 19227849AAAALK3310